Current vaccines for the prevention of herpes zosterGibbons, Allistera; Galor, Anata,bCurrent Opinion in Ophthalmology: July 2018 - Volume 29 - Issue 4 - p 355–359 doi: 10.1097/ICU.0000000000000480 CORNEAL AND EXTERNAL DISORDERS: Edited by Shahzad I. Mian Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Purpose of review To summarize the recent advances in the prevention of herpes zoster. The recent Food and Drug Administration (FDA) approval of an adjuvanted subunit vaccine may have a significant impact on the prevention of herpes zoster ophthalmicus. Recent findings There are currently two commercially available vaccines for the prevention of herpes zoster: a live-attenuated vaccine and a new recombinant subunit vaccine. The latter has been shown to be more effective, have fewer contraindications, but requires two separate inoculations, has higher reactogenicity, and has only short-term postmarketing surveillance. Summary The adjuvanted zoster subunit vaccine offers several advantages over the previously available vaccine. Following the current treatment recommendations, physicians should recommend vaccination to all patients older than 50 years of age with no contraindications, this should also prevent ophthalmic complications of the disease. aUniversity of Miami Miller School of Medicine/ Bascom Palmer Eye Institute bMiami Veterans Affairs Medical Center, Miami, Florida, USA Correspondence to Anat Galor, MD, MSPH, 900 NW 17th Street, Miami, FL 33136, USA. Tel: +1 305 326 6000; fax: +1 305 575 3312; e-mail: firstname.lastname@example.org Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.